Research Partnership Defines Diagnostic Criteria for Sarcopenia, a Debilitating Condition in Older Adults
A series of six special articles published online April 15, 2014, in the Journals of Gerontology: Medical Sciences, derived from the work of the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Sarcopenia Project, provide data-driven diagnostic criteria for sarcopenia, a common and potentially disabling condition in older adults.
These recommendations have the potential to influence treatment decisions, helping identify groups of patients at risk for poor outcomes, in which interventions should be tested, and clarifying categories of sarcopenia patients for insurers, including the Centers for Medicare and Medicaid Services.
Donate and Support Today
Take Action to Support Life-Saving Medical Research
Every dollar counts! Your gift to the FNIH makes our efforts possible. With your help—and in partnership with NIH—the Foundation is advancing biomedical research and training.
Donate with Confidence
The Foundation for the National Institutes of Health was awarded 4-star rating by Charity Navigator for seven consecutive years.
News and Highlights
The National Institutes of Health dedicated the John Edward Porter Neuroscience Center on its Bethesda, Md, campus March 31, with a ceremony and a scientific symposium in honor of the long-serving member of Congress and stalwart supporter of biomedical research for whom it is named. More >>
Jennifer Doudna, Ph.D., a Professor from the University of California, Berkeley, will be the 2014 recipient of the Lurie Prize in the Biomedical Sciences from the Foundation for the National Institutes of Health. Press release Lurie Prize Award Winner, Jennifer Doudna, Ph.D. >>
The National Institutes of Health, along with the Foundation for the NIH, 10 biopharmaceutical companies and several non-profit disease foundations have launched the Accelerating Medicines Partnership, an unprecedented initiative to transform the current model for identifying and validating the most promising biological targets of disease for new diagnostics and drug development. Read the NIH release More >>
I-SPY 2 Graduates Two Promising Drugs that Show Improved Response for Women with HER2-Positive and Triple-Negative Breast Cancer More >>